NEW YORK (GenomeWeb News) – Molecular Devices will distribute ChanTest's portfolio of ion channel and GPCR cell lines under a non-exclusive deal announced today.
As part of the deal, Molecular Devices will also sell ChanTest's cell optimization services to Molecular Devices' customers worldwide using its PatchXpress 7000A, IonWorks Quattro, IonWorks Barracuda, and FLIPR Tetra systems.
Based in Cleveland, ChanTest has more than 145 ion channel and 110 GPCR cell lines
In a statement, Mark Verheyden, president of Sunnyvale, Calif.-based Molecular Devices, said that his firm's customers have been asking for validated cells lines optimized for its systems. "By teaming up with [ChanTest], we are able to provide our customers a complete end-to-end solution for their ion channel and GPCR assays," he said.
Financial and other terms of the deal were not disclosed.